During the past decade, United States Oncology Regulatory Affairs Corporate Office conducted 2 clinical trials. In the 10-year time frame, 2 clinical trials started and 1 clinical trials were completed, i.e. on average, 50% percent of trials that started reached the finish line to date. In the past 5 years, 2 clinical trials started and 1 clinical trials were completed. i.e. 50% of trials that started reached the finish line.

In terms of collaborators to trials, out of the total clinical trials conducted in "United States Oncology Regulatory Affairs Corporate Office" #1 collaborator was "Merck Sharp & Dohme LLC" with 1 trials as a collaborator. Other collaborators include -1 different institutions and companies that were collaborators in the rest 1 trials.

According to Clinical.Site data, the most researched conditions in "United States Oncology Regulatory Affairs Corporate Office" are "Melanoma" (1 trials) and "Relapsed or Refractory Multiple Myeloma" (1 trials). Many other conditions were trialed in "United States Oncology Regulatory Affairs Corporate Office" in a lesser frequency.

Most popular intervention types in "United States Oncology Regulatory Affairs Corporate Office" are "Drug" (2 trials). Other intervention types were less common.

The name of intervention was led by "Carfilzomib" (1 trials), "Dexamethasone" (1 trials), "Lenalidomide" (1 trials), "Pembrolizumab" (1 trials) and "Talimogene laherparepvec" (1 trials). Other intervention names were less common.

The vast majority of trials in "United States Oncology Regulatory Affairs Corporate Office" are 2 trials for "All" genders.

Currently, there are NaN active trials in "United States Oncology Regulatory Affairs Corporate Office". undefined are not yet recruiting, undefined are recruiting, 1 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 1 completed trials in United States Oncology Regulatory Affairs Corporate Office, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in United States Oncology Regulatory Affairs Corporate Office, 0 "Phase 1" clinical trials were conducted, 1 "Phase 2" clinical trials and 1 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".